Evidence map›Paper›PMID 37862103›Full record

Trial reportJournal of medical Internet research2023

Preference Elicitation and Treatment Decision-Making Among Men Diagnosed With Prostate Cancer: Randomized Controlled Trial Results of Healium.

Michael A Diefenbach, Allison Marziliano, Erin K Tagai, Halie Pfister, Emmanuel Lapitan, Simon J Hall, Manish Vira, Said Ibrahim, Kelli Aibel, Alexander Kutikov and 4 more

Registry-linked trialAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Journal of medical Internet research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05800483 (Improving Decision-Making for Low Health Literate Prostate CA Patients), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05800483 nacompletednot on this map

Improving Decision-Making for Low Health Literate Prostate CA Patients

TypeinterventionalSponsorNorthwell HealthRan2020 to 2022Enrolled327ConditionsProstate CancerArmsHealium
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Michael A DiefenbachInstitute of Health System Science, The Feinstein Institutes for Medical Research, Northwell Health, Manhasset, NY, United States.ORCID 0000-0003-2821-1507
Allison MarzilianoInstitute of Health System Science, The Feinstein Institutes for Medical Research, Northwell Health, Manhasset, NY, United States.ORCID 0000-0002-4762-1416
Erin K TagaiCancer Prevention and Control Program, Fox Chase Cancer Center, Temple University Health System, Philadelphia, PA, United States.ORCID 0000-0001-8218-3848
Halie PfisterInstitute of Health System Science, The Feinstein Institutes for Medical Research, Northwell Health, Manhasset, NY, United States.ORCID 0009-0001-4573-5671
Emmanuel LapitanCancer Prevention and Control Program, Fox Chase Cancer Center, Temple University Health System, Philadelphia, PA, United States.ORCID 0000-0003-4986-8524
Simon J HallInstitute of Health System Science, The Feinstein Institutes for Medical Research, Northwell Health, Manhasset, NY, United States.ORCID 0000-0002-1065-0790
Manish ViraInstitute of Health System Science, The Feinstein Institutes for Medical Research, Northwell Health, Manhasset, NY, United States.ORCID 0000-0002-2968-5336
Said IbrahimInstitute of Health System Science, The Feinstein Institutes for Medical Research, Northwell Health, Manhasset, NY, United States.ORCID 0000-0001-5003-512X
Kelli AibelInstitute of Health System Science, The Feinstein Institutes for Medical Research, Northwell Health, Manhasset, NY, United States.ORCID 0000-0003-1834-4293
Alexander KutikovDepartment of Urology, Fox Chase Cancer Center, Temple University Health System, Philadelphia, PA, United States.ORCID 0000-0003-1525-6247
Eric M HorwitzDepartment of Radiation Oncology, Fox Chase Cancer Center, Temple University Health System, Philadelphia, PA, United States.ORCID 0000-0003-2187-317X
Curtis MiyamotoDepartment of Radiation Oncology, Fox Chase Cancer Center, Temple University Health System, Philadelphia, PA, United States.ORCID 0000-0003-3606-3989
Adam C ReeseDepartment of Urology, Fox Chase Cancer Center, Temple University Health System, Philadelphia, PA, United States.ORCID 0000-0001-9587-9852
Suzanne M MillerCancer Prevention and Control Program, Fox Chase Cancer Center, Temple University Health System, Philadelphia, PA, United States.ORCID 0000-0002-7296-9318

Funding

WORD PROCESSING CENTER--COREP30CA006927 · NCI · RESEARCH INST OF FOX CHASE CAN CTR · PI Eric Andrew Ross · 1985 to 2026
$138.8M
NCI NIH HHS P30 CA006927
6 · The paper itself

Abstract

backgroundElicitation of patients' preferences is an integral part of shared decision-making, the recommended approach for prostate cancer decision-making. Existing decision aids for this population often do not specifically focus on patients' preferences. Healium is a brief interactive web-based decision aid that aims to elicit patients' treatment preferences and is designed for a low health literate population.

objectiveThis study used a randomized controlled trial to evaluate whether Healium, designed to target preference elicitation, is as efficacious as Healing Choices, a comprehensive education and decision tool, in improving outcomes for decision-making and emotional quality of life.

methodsPatients diagnosed with localized prostate cancer who had not yet made a treatment decision were randomly assigned to the brief Healium intervention or Healing Choices, a decision aid previously developed by our group that serves as a virtual information center on prostate cancer diagnosis and treatment. Assessments were completed at baseline, 6 weeks, and 3 months post baseline, and included decisional outcomes (decisional conflict, satisfaction with decision, and preparation for decision-making), and emotional quality of life (anxiety/tension and depression), along with demographics, comorbidities, and health literacy.

resultsA total of 327 individuals consented to participate in the study (171 were randomized to the Healium intervention arm and 156 were randomized to Healing Choices). The majority of the sample was non-Hispanic (272/282, 96%), White (239/314, 76%), married (251/320, 78.4%), and was on average 62.4 (SD 6.9) years old. Within both arms, there was a significant decrease in decisional conflict from baseline to 6 weeks postbaseline (Healium, P≤.001; Healing Choices, P≤.001), and a significant increase in satisfaction with one's decision from 6 weeks to 3 months (Healium, P=.04; Healing Choices, P=.01). Within both arms, anxiety/tension (Healium, P=.23; Healing Choices, P=.27) and depression (Healium, P=.001; Healing Choices, P≤.001) decreased from baseline to 6 weeks, but only in the case of depression was the decrease statistically significant.

conclusionsHealium, our brief decision aid focusing on treatment preference elicitation, is as successful in reducing decisional conflict as our previously tested comprehensive decision aid, Healing Choices, and has the added benefit of brevity, making it the ideal tool for integration into the physician consultation and electronic medical record.

trial registrationClinicalTrials.gov NCT05800483; https://clinicaltrials.gov/study/NCT05800483.

Indexed as

Decision MakingProstatic NeoplasmsChildDecision Support TechniquesEmotionsHumansMaleQuality of Lifedecision-makingdecision supportdecision toolemotionalmen’s healthoncologypatient preferencespreferencepreference elicitation softwareprostateprostate cancerrandomized controlled trialRCTweb-based intervention

Identifiers

PMID37862103
PMCPMC10625066

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.